Physician profile
Michael A Engel
NPI 1023112588
$2,594.80
in general payments reported to CMS, 2019-2025
19 companies · $1,685 in 2025
The $1,685 reported for 2025 was more than what 80% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $155 · 2021: $16.61 · 2022: $114 · 2023: $176 · 2024: $111 · 2025: $1,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,253 · Food and Beverage: $720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,252.75 |
| Food and Beverage | $719.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $739.52 | 2024-2025 | |
| Arthrex, INC. | $656.40 | 2025 | |
| Enduromed, LLC | $392.34 | 2023-2025 | |
| Horizon Therapeutics Plc | $268.14 | 2019-2021 | |
| Arteriocyte Medical Systems, INC. | $122.11 | 2019 | |
| Wright Medical Technology, INC. | $93.77 | 2019 | |
| Stryker Corporation | $86.22 | 2022-2024 | Ortholoc 2 Lapifuse, Citrefix |
| Depuy Synthes Sales INC. | $33.60 | 2023 | Motoband |
| Smith+Nephew, INC. | $31.09 | 2022 | |
| Integra Lifesciences Corporation | $25.49 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Nevro Corp. | $24.90 | 2023 | Senza |
| Kerecis Limited | $21.76 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Orthofix Medical, INC. | $21.10 | 2022 | |
| Organogenesis INC. | $20.67 | 2022 | |
| Heron Therapeutics, INC. | $17.23 | 2023 | Zynrelef |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $16.35 | 2023 | Intellis Adaptivestim |
| Electronic Waveform Lab, INC. | $12.52 | 2020 | |
| Merck Sharp & Dohme LLC | $11.59 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$27,500.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Engel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.